首页 › 基金 › Decheng Capital LLC › NAMS

Decheng Capital LLC 对 NAMS 的持仓历史

NEWAMSTERDAM PHARMA COMPANY · 医疗保健

Decheng Capital LLC 在 Q2 2026 的 13F 申报中披露持有 NAMS(NEWAMSTERDAM PHARMA COMPANY)176,887 股,市值约 US$6.0M,约占其申报组合的 0.82%,在其申报持仓中市值排名第 12 位。 Decheng Capital LLC 最近 9 个申报季度中有 9 个季度披露了 NAMS 持仓,最早可追溯至 Q2 2024。

最新持仓 (Q2 2026)176.89K 股
申报持仓市值$5.99M
组合权重0.82%
首次申报Q2 2024
最近变动减持
更新于2026-10-24

最后更新: 2026-10-24 · 来源: SEC EDGAR Form 13F-HR

Decheng Capital LLC 对 NAMS 的持仓演变

Decheng Capital LLC 于 Q2 2024 首次披露 NAMS 持仓:400,000 股(约 US$7.7M)。 该持仓在 Q4 2025 达到峰值 592,057 股,市值约 US$20.8M。 在 9 次申报中,Decheng Capital LLC 2 次增持、4 次减持、2 次保持不变。 最近一期申报(Q2 2026)显示持股 176,887 股、市值约 US$6.0M,环比减持 -148,170 股。。 持仓曾出现大幅变动:Q3 2024 增持约 48% (随后一个季度股价上涨 45%)、Q1 2026 减持约 45% (随后一个季度股价上涨 12%)、Q2 2026 减持约 46% (随后一个季度股价下跌 32%)。

逐季持仓明细

季度股数金额变化
Q2 2024 400.00K $7.68M 新进
Q3 2024 590.00K $9.79M 增持
Q4 2024 770.00K $19.79M 增持
Q1 2025 770.00K $15.76M 持有
Q2 2025 770.00K $13.94M 持有
Q3 2025 657.05K $18.69M 减持
Q4 2025 592.06K $20.77M 减持
Q1 2026 325.06K $10.41M 减持
Q2 2026 176.89K $5.99M 减持

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 NAMS 与 13F 数据

NAMS(NEWAMSTERDAM PHARMA COMPANY)属于医疗保健行业。我们追踪的基金中还有 44 只申报持有 NAMS,申报仓位最大的包括:Frazier Life Sciences Management, L.P. (US$613.0M), RA CAPITAL MANAGEMENT, L.P. (US$323.7M), FCPM III SERVICES B.V. (US$287.7M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 NAMS 的基金

查看 NAMS 的全部基金持有人 →

常见问题

How long has Decheng Capital LLC held NAMS?

Decheng Capital LLC has disclosed NAMS holdings in 9 of the last 9 reported quarters, going back to Q2 2024.

What is Decheng Capital LLC's current position in NAMS?

As of Q2 2026, Decheng Capital LLC holds 176.89K shares of NAMS (NEWAMSTERDAM PHARMA COMPANY), valued at $5.99M, representing 0.82% of its reported portfolio and ranking #12.

Has Decheng Capital LLC been buying or selling NAMS?

In the latest 13F filing (Q2 2026), Decheng Capital LLC reduced its position in NAMS. The position peaked in Q4 2025 at 592.06K shares.

Which other funds hold NAMS?

Other major institutional holders of NAMS include Frazier Life Sciences Management, L.P., RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.